Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483406 | 0.90 | TLR7 (0.49) | TLR7TLR8 | |
| SCHEMBL31006039 | 0.90 | TLR7 (0.49) | TLR7TLR8 | |
| SCHEMBL3814795 | 0.89 | TLR7 (0.69) | TLR7TLR8 | |
| SCHEMBL3820004 | 0.87 | TLR7 (0.52) | TLR7TLR8 | |
| SCHEMBL728254 | 0.87 | TLR7 (0.52) | TLR7TLR8 | |
| SCHEMBL3816411 | 0.87 | TLR7 (0.49) | TLR7TLR8 | |
| SCHEMBL7886381 | 0.86 | TLR7 (0.52) | TLR7TLR8 | |
| SCHEMBL728610 | 0.85 | TLR7 (0.59) | TLR7TLR8 | |
| SCHEMBL5350750 | 0.84 | TLR7 (0.59) | TLR7TLR8 | |
| SCHEMBL3812262 | 0.83 | TLR7 (0.70) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4833466-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| EP-1642580-B1 | Sulfonamide substituted imidazoquinolines | COLEY PHARM GROUP INC (US) | 2009-08-19 | — | — | EP | claimed |
| EP-1198233-B1 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-08-16 | — | — | EP | claimed |
| US-20040029877-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-02-12 | — | — | US | claimed |
| EP-1198233-A4 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2002-07-24 | — | — | EP | claimed |
| EP-1198233-A1 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2002-04-24 | — | — | EP | claimed |
| US-6331539-B1 | INDUCE BIOSYNTHESIS OF INTERFERON ALPHA IN ANIMALS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-12-18 | — | — | US | claimed |
| WO-2000076519-A1 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029877-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 59/4885TLR8 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.